TNF-α blockers such as infliximab have been linked to an increased risk of infections, especially opportunistic fungal infections, with reported variable incidences of invasive fungal infection ranging from 6% to 50% [35,36,37,38,39,40,41]. This evidence concerns the gene TNF and fungal infectious disease.